47 results on '"Yakoub‐Agha, Ibrahim"'
Search Results
2. Multiple Myeloma
3. The Value of CAR-T-cell Immunotherapy in Cancer
4. GoCART
5. Education Needs for Nurses in Adult and Paediatric Units
6. Educational Needs for Physicians
7. The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers
8. Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma
9. Long-Term Follow-Up and Late Effects
10. Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia
11. Management of Myelotoxicity (Aplasia) and Infectious Complications
12. Immune Monitoring
13. Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
14. Management of Cytokine Release Syndrome (CRS) and HLH
15. Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia
16. Myeloid Malignancies
17. Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
18. Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL
19. Chronic Lymphocytic Leukaemia
20. Indolent Lymphomas
21. Developments in Solid Tumours
22. Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma
23. Adult Acute Lymphoblastic Leukaemia
24. Developments in Other Haematological Malignancies: Other Lymphoid Malignancies
25. What Defines a Good Tumour Antigen?
26. CART Initiatives in Europe
27. Tumour Escape from CAR-T Cells
28. Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells
29. Point-of-Care Production of CAR-T Cells
30. Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment
31. Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility
32. Genetic Engineering of Autologous or Allogeneic Immune Effector Cells
33. How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified?
34. Patient Referral
35. What do Patients Want? The Importance of Patient-reported Outcomes
36. Role of Pharmacists
37. Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma
38. ICU
39. Management of Hypogammaglobulinaemia and B-Cell Aplasia
40. Lymphodepleting Conditioning Regimens
41. Bridging Chemotherapy: Multiple Myeloma
42. Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
43. Mantle Cell Lymphoma
44. Paediatric Acute Lymphoblastic Leukaemia (ALL)
45. Structure of and Signalling Through Chimeric Antigen Receptor
46. Treatment Coverage and Reimbursement
47. Educational Needs for Cell Processing Facility Personnel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.